Reporting Checklist for Nature Neuroscience

This checklist is used to ensure good reporting standards and to improve the reproducibility of published results. For more information, please read Reporting Life Sciences Research.

Please note that in the event of publication, it is mandatory that authors include all relevant methodological and statistical information in the manuscript.

## Statistics reporting, by figure

- Please specify the following information for each panel reporting quantitative data, and where each item is reported (section, e.g. Results, & paragraph number).
- Each figure legend should ideally contain an exact sample size (n) for each experimental group/condition, where n is an exact number and not a range, a clear definition of how n is defined (for example x cells from x slices from x animals from x litters, collected over x days), a description of the statistical test used, the results of the tests, any descriptive statistics and clearly defined error bars if applicable.
- For any experiments using custom statistics, please indicate the test used and stats obtained for each experiment.
- Each figure legend should include a statement of how many times the experiment shown was replicated in the lab; the details of sample collection should be sufficiently clear so that the replicability of the experiment is obvious to the reader.
- For experiments reported in the text but not in the figures, please use the paragraph number instead of the figure number.

Note: Mean and standard deviation are not appropriate on small samples, and plotting independent data points is usually more informative. When technical replicates are reported, error and significance measures reflect the experimental variability and not the variability of the biological process; it is misleading not to state this clearly.

<table>
<thead>
<tr>
<th>TEST USED</th>
<th>n</th>
<th>DESCRiptive STATS (AVERAGE, VARIANCE)</th>
<th>P VALUE</th>
<th>DEGREES OF FREEDOM &amp; F/T/Z/R/ETC VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FIGURE NUMBER</td>
<td>WHICH TEST</td>
<td>SECTION &amp; PARAGRAPH #</td>
<td>EXACT VALUE</td>
<td>DEFINED?</td>
</tr>
<tr>
<td>1a</td>
<td>one-way ANOVA</td>
<td>Fig. legend</td>
<td>9, 9, 10, 15 mice from at least 3 litters/group</td>
<td>Methods para 8</td>
</tr>
<tr>
<td>results para 6</td>
<td>unpaired t-test</td>
<td>Results para 6</td>
<td>15 slices from 10 mice</td>
<td>Results para 6</td>
</tr>
<tr>
<td>FIGURE NUMBER</td>
<td>TEST USED</td>
<td>n</td>
<td>DESCRIPTIVE STATS (AVERAGE, VARIANCE)</td>
<td>P VALUE</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
<td>---</td>
<td>--------------------------------------</td>
<td>---------</td>
</tr>
<tr>
<td>2b</td>
<td>Area Under the Curve (AUC), bootstrap, confidence interval (CI)</td>
<td>1005</td>
<td>Number of replay events with grid cell active</td>
<td>Fig2b shows SD</td>
</tr>
<tr>
<td>3a</td>
<td>Area Under the Curve (AUC), bootstrap, Cls</td>
<td>315 (reverse events), 639 (forward events)</td>
<td>Number of forward and reverse replay events</td>
<td>Fig3a shows SD</td>
</tr>
<tr>
<td>3b</td>
<td>Repeated Measures ANOVA</td>
<td>315 (reverse events), 639 (forward events)</td>
<td>Number of forward and reverse replay events per time shift</td>
<td>Fig3b shows SD</td>
</tr>
<tr>
<td>2</td>
<td>Spearman rank order correlation and independent samples t-test</td>
<td>43</td>
<td>Number of grid cells</td>
<td>Figure 2c</td>
</tr>
<tr>
<td>3c</td>
<td>Parametric shuffle vs null distribution</td>
<td>4382</td>
<td>Number of putative events</td>
<td>Figure 2a titles</td>
</tr>
<tr>
<td>3</td>
<td>Paired t-test</td>
<td>43</td>
<td>Number of grid cells</td>
<td>n/a</td>
</tr>
<tr>
<td>3</td>
<td>Area Under the Curve (AUC), bootstrap, Cls</td>
<td>1005</td>
<td>Number of replay events with grid cell active</td>
<td>SD shown in SI fig8</td>
</tr>
<tr>
<td>3</td>
<td>Area Under the Curve (AUC), bootstrap, Cls</td>
<td>395</td>
<td>Number of replay events with grid cell active</td>
<td>SD shown in SI fig10</td>
</tr>
<tr>
<td>4</td>
<td>Wilcoxon signed rank</td>
<td>85</td>
<td>Number of grid ratemaps</td>
<td>mean = 0.10, sem = 0.033</td>
</tr>
<tr>
<td>5</td>
<td>Chi-square</td>
<td>1826</td>
<td>Number of replay events</td>
<td>proportions</td>
</tr>
<tr>
<td>5</td>
<td>Down sampling data samples to equate N</td>
<td>315</td>
<td>Number of reverse replay events</td>
<td>Not stated - can be included on request</td>
</tr>
</tbody>
</table>

Area Under the Curve (AUC), bootstrap, confidence interval (CI), reverse events, forward events, number of forward and reverse events per time shift.

Confidence Interval: [-1.2999, -0.7680]. Reverse CI: [-1.70006, -0.1387], Forward CI: [-3.6289, -2.161], Forward vs Reverse CI: [-2.8902, -0.7782].

Reverse: p = 0.0093, Forward: p < 0.0001, Forward vs Reverse: p = 0.0006.

Spearman: p < 0.0001, t-test: p = 0.001.

Spearman r = 0.61, t-test(35) = 3.57.

Reverse: F(24,1646) = 0.37, Forward: F(24,4320) = 9.26.

Reverse CI: [-1.70006, -0.1387], Forward CI: [-3.6289, -2.161], Forward vs Reverse CI: [-2.8902, -0.7782].

Spearman r = 0.61, t-test(35) = 3.57.

Confidence Interval: [-1.2999, -0.7680]. Reverse CI: [-1.70006, -0.1387], Forward CI: [-3.6289, -2.161], Forward vs Reverse CI: [-2.8902, -0.7782].

Reverse: p = 0.0093, Forward: p < 0.0001, Forward vs Reverse: p = 0.0006.

Spearman: p < 0.0001, t-test: p = 0.001.

Spearman r = 0.61, t-test(35) = 3.57.

Reverse: F(24,1646) = 0.37, Forward: F(24,4320) = 9.26.
### Representative figures

1. Are any representative images shown (including Western blots and immunohistochemistry/staining) in the paper? If so, what figure(s)?

Yes, example ratemaps and putative event in figure 1 and six decoded events in figure 2 as well as three ratemaps.

2. For each representative image, is there a clear statement of how many times this experiment was successfully repeated and a discussion of any limitations in repeatability? If so, where is this reported (section, paragraph #)?

Yes, the exact number of example illustrations is now specified in each figure caption and this can be referenced against SI table 1 which species the number of animals, cells and events.

### Statistics and general methods

1. Is there a justification of the sample size? If so, how was it justified? Where (section, paragraph #)?

Even if no sample size calculation was performed, authors should report why the sample size is adequate to measure their effect size.

6 animals (635 cells), exceeding precedent set by previous replay papers

2. Are statistical tests justified as appropriate for every figure? Where (section, paragraph #)?

Tests are described and justified in the Online Methods
a. If there is a section summarizing the statistical methods in the methods, is the statistical test for each experiment clearly defined?

Yes

b. Do the data meet the assumptions of the specific statistical test you chose (e.g. normality for a parametric test)?

Where is this described (section, paragraph #)?

For all of the main analyses we use non-parametric shuffle tests - as is standard in this field- that don't require assumptions about normality and equality of variance. For the few parametric tests we don't formally test whether our data meet the assumptions of tests, and we state this clearly in the Online Methods, as requested by Nature Neuroscience.

All tests are described in the Online Methods

c. Is there any estimate of variance within each group of data?

Is the variance similar between groups that are being statistically compared?

Where is this described (section, paragraph #)?

For all of the main analyses we use non-parametric shuffle tests - as is standard in this field- that don't require assumptions about normality and equality of variance. For the few parametric tests we don't formally test whether our data meet the assumption of equality of variance, and we state this clearly in the Online Methods, as requested by Nature Neuroscience.

All tests are described in the Online Methods

d. Are tests specified as one- or two-sided?

Yes, all are two-sided

e. Are there adjustments for multiple comparisons?

We do not make multiple comparisons

3. To promote transparency, Nature Neuroscience has stopped allowing bar graphs to report statistics in the papers it publishes. If you have bar graphs in your paper, please make sure to switch them to dot-plots (with central and dispersion statistics displayed) or to box-and-whisker plots to show data distributions.

n/a

4. Are criteria for excluding data points reported?

Was this criterion established prior to data collection?

Where is this described (section, paragraph #)?

We clearly explain data inclusion criteria and state data that meet these criteria were in included in all analyses, see Online Methods

5. Define the method of randomization used to assign subjects (or samples) to the experimental groups and to collect and process data.

If no randomization was used, state so.

Where does this appear (section, paragraph #)?

Randomisation was not applicable, we do not use experimental groups. See Online Methods

6. Is a statement of the extent to which investigator knew the group allocation during the experiment and in assessing outcome included?

If no blinding was done, state so.

Where (section, paragraph #)?

n/a, see #5
7. For experiments in live vertebrates, is a statement of compliance with ethical guidelines/regulations included?  
   Where (section, paragraph #)?  
   **Yes**, in Online Methods (Animals and Surgery sub-section)

8. Is the species of the animals used reported?  
   Where (section, paragraph #)?  
   **Yes**, in Online Methods

9. Is the strain of the animals (including background strains of KO/transgenic animals used) reported?  
   Where (section, paragraph #)?  
   **Yes**, in Online Methods

10. Is the sex of the animals/subjects used reported?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

11. Is the age of the animals/subjects reported?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

12. For animals housed in a vivarium, is the light/dark cycle reported?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

13. For animals housed in a vivarium, is the housing group (i.e. number of animals per cage) reported?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

14. For behavioral experiments, is the time of day reported (e.g. light or dark cycle)?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

15. Is the previous history of the animals/subjects (e.g. prior drug administration, surgery, behavioral testing) reported?  
    Where (section, paragraph #)?  
    **Yes**, in Online Methods

   a. If multiple behavioral tests were conducted in the same group of animals, is this reported?  
      Where (section, paragraph #)?  
      **N/A**

16. If any animals/subjects were excluded from analysis, is this reported?  
    Where (section, paragraph #)?  
    None excluded, see Online Methods

   a. How were the criteria for exclusion defined?  
      Where is this described (section, paragraph #)?  
      **N/A**
b. Specify reasons for any discrepancy between the number of animals at the beginning and end of the study.

Where is this described (section, paragraph #)?

n/a

Reagents

1. Have antibodies been validated for use in the system under study (assay and species)?
   
a. Is antibody catalog number given?
   
   Where does this appear (section, paragraph #)?

   n/a

b. Where were the validation data reported (citation, supplementary information, Antibodypedia)?

   Where does this appear (section, paragraph #)?

   n/a

2. Cell line identity
   
a. Are any cell lines used in this paper listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample?

   Where (section, paragraph #)?

   n/a

b. If yes, include in the Methods section a scientific justification of their use--indicate here in which section and paragraph the justification can be found.

   n/a

c. For each cell line, include in the Methods section a statement that specifies:
   - the source of the cell lines
   - have the cell lines been authenticated? If so, by which method?
   - have the cell lines been tested for mycoplasma contamination?

   Where (section, paragraph #)?

   n/a
Data availability

Provide a Data availability statement in the Methods section under “Data availability”, which should include, where applicable:

- Accession codes for deposited data
- Other unique identifiers (such as DOIs and hyperlinks for any other datasets)
- At a minimum, a statement confirming that all relevant data are available from the authors
- Formal citations of datasets that are assigned DOIs
- A statement regarding data available in the manuscript as source data
- A statement regarding data available with restrictions

See our data availability and data citations policy page for more information.

Data deposition in a public repository is mandatory for:

- Protein, DNA and RNA sequences
- Macromolecular structures
- Crystallographic data for small molecules
- Microarray data

Deposition is strongly recommended for many other datasets for which structured public repositories exist; more details on our data policy are available here. We encourage the provision of other source data in supplementary information or in unstructured repositories such as Figshare and Dryad.

We encourage publication of Data Descriptors (see Scientific Data) to maximize data reuse.

Where is the Data Availability statement provided (section, paragraph #)?

We state data can be made available upon request. Moreover, we submit analyses software used to obtain our results.

See Data /code availability sub-section of Online Methods

Computer code/software

Any custom algorithm/software that is central to the methods must be supplied by the authors in a usable and readable form for readers at the time of publication. However, referees may ask for this information at any time during the review process.

1. Identify all custom software or scripts that were required to conduct the study and where in the procedures each was used.

   Several custom scripts - available on request

2. If computer code was used to generate results that are central to the paper’s conclusions, include a statement in the Methods section under “Code availability” to indicate whether and how the code can be accessed. Include version information as necessary and any restrictions on availability.

   A statement of code availability is included in Online Methods (Data availability sub-section) and core functions are made available as Supplementary Software.

Human subjects
1. Which IRB approved the protocol?
   Where is this stated (section, paragraph #)?
   n/a

2. Is demographic information on all subjects provided?
   Where (section, paragraph #)?
   n/a

3. Is the number of human subjects, their age and sex clearly defined?
   Where (section, paragraph #)?
   n/a

4. Are the inclusion and exclusion criteria (if any) clearly specified?
   Where (section, paragraph #)?
   n/a

5. How well were the groups matched?
   Where is this information described (section, paragraph #)?
   n/a

6. Is a statement included confirming that informed consent was obtained from all subjects?
   Where (section, paragraph #)?
   n/a

7. For publication of patient photos, is a statement included confirming that consent to publish was obtained?
   Where (section, paragraph #)?
   n/a

---

**fMRI studies**

For papers reporting functional imaging (fMRI) results please ensure that these minimal reporting guidelines are met and that all this information is clearly provided in the methods:

1. Were any subjects scanned but then rejected for the analysis after the data was collected?
   n/a

   a. If yes, is the number rejected and reasons for rejection described?
      Where (section, paragraph #)?
      n/a

2. Is the number of blocks, trials or experimental units per session and/or subjects specified?
   Where (section, paragraph #)?
   n/a

3. Is the length of each trial and interval between trials specified?
   n/a

4. Is a blocked, event-related, or mixed design being used? If applicable, please specify the block length or how the event-related or mixed design was optimized.
   n/a
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| 5. | Is the task design clearly described?  
Where (section, paragraph #)? | n/a |
| 6. | How was behavioral performance measured? | n/a |
| 7. | Is an ANOVA or factorial design being used? | n/a |
| 8. | For data acquisition, is a whole brain scan used?  
If not, state area of acquisition.  
a. How was this region determined? | n/a |
| 9. | Is the field strength (in Tesla) of the MRI system stated?  
a. Is the pulse sequence type (gradient/spin echo, EPI/spiral) stated?  
b. Are the field-of-view, matrix size, slice thickness, and TE/TR/flip angle clearly stated? | n/a |
| 10. | Are the software and specific parameters (model/functions, smoothing kernel size if applicable, etc.) used for data processing and pre-processing clearly stated? | n/a |
| 11. | Is the coordinate space for the anatomical/functional imaging data clearly defined as subject/native space or standardized stereotaxic space, e.g., original Talairach, MNI305, ICBM152, etc? Where (section, paragraph #)? | n/a |
| 12. | If there was data normalization/standardization to a specific space template, are the type of transformation (linear vs. nonlinear) used and image types being transformed clearly described? Where (section, paragraph #)? | n/a |
| 13. | How were anatomical locations determined, e.g., via an automated labeling algorithm (AAL), standardized coordinate database (Talairach daemon), probabilistic atlases, etc.? | n/a |
| 14. | Were any additional regressors (behavioral covariates, motion etc) used? | n/a |
| 15. | Is the contrast construction clearly defined? | n/a |
| 16. | Is a mixed/random effects or fixed inference used?  
a. If fixed effects inference used, is this justified? | n/a |
| 17. | Were repeated measures used (multiple measurements per subject)? | n/a |
### Additional comments

| Additional Comments | n/a |